Court Approves $7.25 Billion Bayer Settlement Over Roundup Cancer Claims
St. Louis Circuit Judge Timothy Boyer approved Bayer's Roundup cancer settlement on Friday. Bayer will pay up to $7.25 billion over as many as 21 years.
- $10,000 to $165,000: the range of average payouts per participant.
- $16 billion was set aside earlier; this deal comes on top.
- $10.9 billion settled much of the litigation in 2020.
- 46% drop in Bayer's share price since buying Monsanto.
Why it matters: The settlement covers people already sick and those diagnosed later after pre-February exposure. Bayer gains financial certainty, and claimants get guaranteed payments instead of uncertain trials.
- In June, the Supreme Court barred state failure-to-warn claims over Roundup.
- The WHO cancer agency says glyphosate is probably carcinogenic; the EPA disagrees.
How 25 sources split on this story
Where they split: Plaintiffs' attorneys disagree on whether the payouts are fair compensation or too small and restrictive.
Center coverage, 13 sources: The center presents the deal as a court-approved resolution, stressing the unsettled science and the Supreme Court ruling that weakened plaintiffs' cases.
Left coverage, 6 sources: The left frames the approval as a judge closing out years of cancer claims, giving space to objectors who call the payouts too low.
What’s next: The approval could be appealed. About 200 federal cases outside the deal are still being litigated, Bayer says.
- Bayer will make annual payments into a special fund.
- Will objecting attorneys appeal the approval?
- Will Bayer pull Roundup from U.S. agricultural markets?
























